Insmed, Inc. $INSM Position Lowered by Elevation Point Wealth Partners LLC

Elevation Point Wealth Partners LLC trimmed its position in Insmed, Inc. (NASDAQ:INSM) by 50.4% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,685 shares of the biopharmaceutical company’s stock after selling 1,712 shares during the period. Elevation Point Wealth Partners LLC’s holdings in Insmed were worth $170,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. ORG Partners LLC grew its position in shares of Insmed by 220.2% in the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 196 shares in the last quarter. Hilltop National Bank acquired a new stake in shares of Insmed during the 2nd quarter valued at approximately $28,000. FNY Investment Advisers LLC bought a new position in Insmed during the second quarter worth $33,000. LRI Investments LLC acquired a new position in Insmed in the second quarter worth $59,000. Finally, Strategic Investment Solutions Inc. IL bought a new stake in Insmed during the first quarter valued at $79,000.

Insiders Place Their Bets

In related news, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $194.00, for a total value of $5,820,000.00. Following the completion of the transaction, the insider owned 36,461 shares in the company, valued at $7,073,434. This represents a 45.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Elizabeth M. Anderson sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $204.58, for a total transaction of $1,022,900.00. Following the transaction, the director directly owned 58,729 shares in the company, valued at approximately $12,014,778.82. The trade was a 7.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 257,922 shares of company stock valued at $44,556,283. Corporate insiders own 3.00% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on INSM shares. JPMorgan Chase & Co. raised their price target on shares of Insmed from $111.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 20th. Cowen reiterated a “buy” rating on shares of Insmed in a research note on Thursday, November 20th. Stifel Nicolaus raised their target price on shares of Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada increased their price target on Insmed from $139.00 to $215.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Nineteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and an average price target of $175.53.

Insmed Stock Performance

Shares of INSM stock opened at $206.43 on Monday. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $209.77. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The firm has a market capitalization of $44.02 billion, a price-to-earnings ratio of -36.15 and a beta of 1.05. The business has a 50 day simple moving average of $173.90 and a 200 day simple moving average of $130.53.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. During the same quarter last year, the firm posted ($1.27) EPS. The company’s revenue was up 52.4% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.